Table 3.
Treatment-emergent adverse events in the VA versus VAH group
| AE | VA | VAH | P | |||
|---|---|---|---|---|---|---|
| (n = 18) | (n = 14) | |||||
| All grades, n (%) | Grade ≥ 3, n (%) | All grades, n (%) | Grade ≥ 3, n (%) | All grades | Grade ≥ 3 | |
| Anemia | 18(100) | 12(66.7) | 14(100) | 10(71.4) | — | 0.773 |
| Neutropenia | 18(100) | 15(83.3) | 14(100) | 12(85.7) | — | 0.854 |
| Thrombocytopenia | 18(100) | 13(72.2) | 14(100) | 11(78.6) | — | 0.681 |
| Febrile neutropenia | 7(38.9) | 5(27.8) | 7(50) | 4(28.6) | 0.53 | 0.96 |
| Pneumonia | 8(44.4) | 0 | 5(35.7) | 0 | 0.618 | — |
| Fungal pneumonia | 1(5.6) | 1(5.6) | 0 | 0 | — | — |
| Sepsis | 0 | 0 | 1(7.1) | 1(7.1) | — | — |
| Urinary tract infection | 0 | 0 | 1(7.1) | 1(7.1) | — | — |
| Viral infection | 0 | 0 | 0 | 0 | — | — |
| Elevated liver enzymes | 1(5.6) | 0 | 1(7.1) | 0 | 0.854 | — |
| Nausea, Vomiting | 8(44.4) | 0 | 4(28.6) | 0 | 0.358 | — |
| Diarrhea | 0 | 0 | 1(7.1) | 0 | — | — |
| Bleeding (vaginal, gastrointestinal, pulmonary) | 1(5.6) | 0 | 0 | 0 | — | — |
| Allergic reaction | 1(5.6) | 0 | 3(21.4) | 0 | 0.178 | — |
| Heart failure | 0 | 0 | 0 | 0 | — | — |
| Tumor lysis syndrome | 0 | 0 | 0 | 0 | — | — |